Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FLT PET vs MRI for Recurrent Glioma
NCT02241668Withdrawn
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jun 2015
- Primary completion
- Jun 2015
- Modality
- Small Molecules
01
Overview
Open-label, single-arm trial of fluorothymidine F-18 in glioma, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Performance of Fluoro-L-Thymidine Positron Emission Tomography (FLT PET) and Perfusion Magnetic Resonance Imaging (MRI) in the Diagnosis of Recurrent High-Grade Glial Tumor at 1 day. Planned start Jun 2015; status: withdrawn.
02
Drugs
fluorothymidine F-18
03
Conditions
glioma
Beyond the preview
Go deeper on NCT02241668.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02241668.